Targeted Therapies

Preclinical Candidate AVJ16 Blocks IGF2BP1 to Halt Lung Tumor Growth in Models

Peer-reviewed findings in Oncogene highlight a selective attack on cancer cells by inhibiting an RNA-binding protein.